Sumagen Canada Inc, a biotechnology company and part of the Curo Group, made an announcement yesterday saying Phase I clinical trials of their groundbreaking HIV vaccine has shown extremely promising results. The vaccine, SAV001-H, had been in development for years.
According to communications.uwo.ca, the vaccine was “developed by Dr. Chil-Yong Kang and his team at Western’s Schulich School of Medicine & Dentistry, with the support of Sumagen Canada, the vaccine (SAV001-H) holds tremendous promise for success in the final phases of clinical testing now that the first hurdle has been accomplished”.
Clinical human trials for the vaccine started back in March of 2012 and were completed in August of this year. “This trial was a randomized, observer-blinded, placebo-controlled study of killed whole HIV-1 vaccine (SAV001-H) following intramuscular (IM) administration. HIV-infected, asymptomatic men and women, 18 to 50 years of age, have been enrolled in this study and randomized into two treatment groups to administer killed whole HIV-1 vaccine (SAV001-H) or placebo”.
As one of only a small number of similar vaccines worldwide, the completion of these trials holds great promise for the medical community and most importantly, for the over 30 million people who live with the HIV virus today.
This latest development is a long time coming, as the first clinical trials for a vaccine to combat the HIV virus started back in 1987 and follows shortly after HVTN 505 immunizations were stopped this year “due to lack of efficacy”, according to http://www.niaid.nih.gov.
CEO of the South Korean company, Jung-Gee Cho, said in a press release that “Even though Sumagen has struggled and spent a much longer time to overcome manufacturing difficulties and to meet the USFDA’s requirements, we have accomplished successfully Phase I Clinical Trial of SA001-H and proven that there is no safety concern of SAV001-H in human administration,” said Jung-Gee Cho, Sumagen CEO. “We are now prepared to take the next steps towards Phase II and Phase III clinical trials. We are opening the gate to pharmaceutical companies, government, and charity organization for collaboration to be one step closer to the first commercialized HIV vaccine.”
As HIV gains about 50,000 new infections every year, the medical community continues to find ways to fight the epidemic. Part of this fight has led to the development of drugs which actually prevent the infection before it happens, and an event at the GCCR tomorrow night with speakers from VCU’s medical community hopes to [...]